SPDL1 and cancer: Scirocchi et al. suggested that high sPD-L1 levels in cancer patients indicate worse survival and may be a helpful biomarker for qualification for immunotherapy, thus improving the efficacy of ICIs and avoiding unnecessary treatment [11].